Eurofins expands its clinical diagnostic footprint with the acquisition of Hygel in Germany

Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services, announces the acquisition of MVZ für Laboratoriumsmedizin am Hygiene-Institut GmbH (“Hygel”), a group of clinical diagnostic laboratories headquartered in Gelsenkirchen, Germany. The transaction is expected to close at the beginning of July, subject to the fulfilment of customary closing conditions.

Founded in 1902, Hygel has developed into one of the largest clinical diagnostics providers in North Rhine-Westphalia, the most populous federal state in Germany, with access to over 900 physicians, 120 hospitals and around 20 local health authorities. As a reference clinical laboratory, Hygel serves more than 50% of the healthcare industry in the Northern Ruhr area and Iserlohn region, with multiple accreditations from both private and public health authorities and agencies. The company employs 370 staff across its 3 main sites as well as in laboratories that it operates for 4 local hospitals, and generated revenues in excess of EUR 35m in 2016.

The acquisition of Hygel provides Eurofins entry into the clinical diagnostic testing market in Germany, and reinforces the Group’s footprint to serve healthcare professionals in Europe. In return, Eurofins’ vast analytical portfolio and technical resources, as well as the Group’s world class laboratory and systems infrastructure, should support the further development of Hygel’s portfolio of diagnostic tests and services, as well as the expansion of its footprint and client reach in the rest of the country.

Comment from Dr. Astrid Dirkes-Kersting, Managing Director, Hygel: “We are excited to be joining the Eurofins family of laboratories and look forward to the next phase of our development within the Group. We are confident that with access to Eurofins’ network and technical competencies, we should be able to expand our analytical portfolio and services to benefit all our existing and future clients.”

Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of Hygel expands Eurofins’ clinical diagnostic footprint in Europe, and reinforces the platform on which to deploy the Group’s technical know-how and proprietary technologies, including our competencies in specialty diagnostic testing. We are committed to supporting Hygel in further developing its service offering and its geographic footprint to better serve the healthcare industry in Germany.”

For more information, please contact:

Investor Relations
Eurofins Scientific
Phone: +32 2 766 1620
E-mail: ir@eurofins.com

Notes for the editor:

Eurofins – a global leader in bio-analysis
Eurofins Scientific through its subsidiaries (hereinafter sometimes “Eurofins” or “the Group”) believes it is the world
leader in food, environment and pharmaceutical products testing and that it is also one of the global independent
market leaders in certain testing and laboratory services for agroscience, genomics, discovery pharmacology and for supporting clinical studies. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic
testing in Europe and the USA. With over 28,000 staff in 310 laboratories across 39 countries, Eurofins offers a
portfolio of over 130,000 analytical methods for evaluating the safety, identity, composition, authenticity, origin and
purity of biological substances and products, as well as for innovative clinical diagnostic. The Group objective is to
provide its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of
biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive
range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the expanding demands of regulatory
authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters
EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The
forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’
management as of the date of this release. These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.